Tags

Type your tag names separated by a space and hit enter

Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy.
J Transl Med. 2018 08 13; 16(1):223.JT

Abstract

BACKGROUND

Circulating exosomes from prostate cancer (PCa) patients undergoing radiotherapy are attractive candidate biomarkers for monitoring treatment response. Multiple workflows for isolation and content characterization of exosomes in biofluids have been attempted. We report a protocol to isolate and characterize exosomal miRNAs content and assess radiation-induced changes.

METHODS

In this pilot study, we performed targeted exosomal miRNA profiling of 25 serum samples obtained from PCa patients with intermediate- and high-risk disease treated with curative radiotherapy (RT), and controls. Post-treatment blood samples were collected at least 28 days after radiation therapy as a paired follow-up sample. The complete workflow consisted of two phases: I) filtration and polyethylene glycol salt precipitation phase which enriched particles below 200 nm in size followed by characterization using electron microscopy, and II) flow cytometry. Finally, miRNA expression analysis between untreated and treated patient samples was performed using RNA extraction kit, and qRT-PCR.

RESULTS

In our preliminary data, 1 ml of serum from PCa patients showed higher exosomal concentration (3.68E+10) compared to controls (6.07E+08). The overall expression of exosomes after RT was found to be higher compared to untreated samples; the median value changed from 3.68E+10 to 5.40E+10; p = 0.52. Using electron microscopy, we were able to visualize cup-shaped vesicles with morphology and size compatible with exosomes. The bead-based flow cytometry showed positivity for exosomal tetraspanins surface markers CD63 and CD9. All five miRNAs (hsa-let-7a-5p, hsa-miR-141-3p, hsa-miR-145-5p, hsa-miR-21-5p, hsa-miR-99b-5p) have been identified in exosomes. Despite overall changes in hsa-let-7a-5p expression after radiation, the difference was significant only in the high-risk group (p = 0.037). In addition, the radiation response to hsa-miR-21-5p was elevated in the high-risk group compared to the intermediate group (p = 0.036).

CONCLUSIONS

Herewith, we demonstrated a protocol for isolation of serum exosomes and exosomal miRNA amplification. The recovery of exosomal miRNAs and their differential expression after radiation treatment suggests promising biomarker potential that requires further investigation in larger patient cohorts.

Authors+Show Affiliations

Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. alan.dalpra@med.miami.edu. Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA. alan.dalpra@med.miami.edu.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30103771

Citation

Malla, Bijaya, et al. "Protocol for Serum Exosomal miRNAs Analysis in Prostate Cancer Patients Treated With Radiotherapy." Journal of Translational Medicine, vol. 16, no. 1, 2018, p. 223.
Malla B, Aebersold DM, Dal Pra A. Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy. J Transl Med. 2018;16(1):223.
Malla, B., Aebersold, D. M., & Dal Pra, A. (2018). Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy. Journal of Translational Medicine, 16(1), 223. https://doi.org/10.1186/s12967-018-1592-6
Malla B, Aebersold DM, Dal Pra A. Protocol for Serum Exosomal miRNAs Analysis in Prostate Cancer Patients Treated With Radiotherapy. J Transl Med. 2018 08 13;16(1):223. PubMed PMID: 30103771.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy. AU - Malla,Bijaya, AU - Aebersold,Daniel M, AU - Dal Pra,Alan, Y1 - 2018/08/13/ PY - 2018/04/09/received PY - 2018/07/30/accepted PY - 2018/8/15/entrez PY - 2018/8/15/pubmed PY - 2019/6/21/medline KW - Biomarker KW - Exosomes KW - Prostate cancer KW - Radiation oncology KW - miRNA SP - 223 EP - 223 JF - Journal of translational medicine JO - J Transl Med VL - 16 IS - 1 N2 - BACKGROUND: Circulating exosomes from prostate cancer (PCa) patients undergoing radiotherapy are attractive candidate biomarkers for monitoring treatment response. Multiple workflows for isolation and content characterization of exosomes in biofluids have been attempted. We report a protocol to isolate and characterize exosomal miRNAs content and assess radiation-induced changes. METHODS: In this pilot study, we performed targeted exosomal miRNA profiling of 25 serum samples obtained from PCa patients with intermediate- and high-risk disease treated with curative radiotherapy (RT), and controls. Post-treatment blood samples were collected at least 28 days after radiation therapy as a paired follow-up sample. The complete workflow consisted of two phases: I) filtration and polyethylene glycol salt precipitation phase which enriched particles below 200 nm in size followed by characterization using electron microscopy, and II) flow cytometry. Finally, miRNA expression analysis between untreated and treated patient samples was performed using RNA extraction kit, and qRT-PCR. RESULTS: In our preliminary data, 1 ml of serum from PCa patients showed higher exosomal concentration (3.68E+10) compared to controls (6.07E+08). The overall expression of exosomes after RT was found to be higher compared to untreated samples; the median value changed from 3.68E+10 to 5.40E+10; p = 0.52. Using electron microscopy, we were able to visualize cup-shaped vesicles with morphology and size compatible with exosomes. The bead-based flow cytometry showed positivity for exosomal tetraspanins surface markers CD63 and CD9. All five miRNAs (hsa-let-7a-5p, hsa-miR-141-3p, hsa-miR-145-5p, hsa-miR-21-5p, hsa-miR-99b-5p) have been identified in exosomes. Despite overall changes in hsa-let-7a-5p expression after radiation, the difference was significant only in the high-risk group (p = 0.037). In addition, the radiation response to hsa-miR-21-5p was elevated in the high-risk group compared to the intermediate group (p = 0.036). CONCLUSIONS: Herewith, we demonstrated a protocol for isolation of serum exosomes and exosomal miRNA amplification. The recovery of exosomal miRNAs and their differential expression after radiation treatment suggests promising biomarker potential that requires further investigation in larger patient cohorts. SN - 1479-5876 UR - https://www.unboundmedicine.com/medline/citation/30103771/Protocol_for_serum_exosomal_miRNAs_analysis_in_prostate_cancer_patients_treated_with_radiotherapy_ DB - PRIME DP - Unbound Medicine ER -